Chase Therapeutics
Acquired- Headquarters
- Mountain View, California
- Employees
- 1–10
- Business Model
- B2B
About
Chase Therapeutics Corporation was an early-stage specialty pharmaceutical company focused on developing novel dopamine agonist combination therapies for brain diseases, with lead programs targeting treatment-resistant depression (CTC-501/ALTO-207) and Parkinson's disease (CTC-413/ALTO-208). The company completed Phase 2a clinical trials for both candidates, demonstrating statistically significant clinical effects. In June 2025, Alto Neuroscience acquired Chase Therapeutics' full pipeline via an asset purchase agreement for $1.75 million upfront plus up to $71.5 million in future milestone payments.
Summary
Chase Therapeutics is a Biotech company based in Mountain View, United States.
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...